Comparable stake leader
Amit Kumar
SEC ownership of Anixa Biosciences Inc
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000715446.
Disclosed value leader
Amit Kumar
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ANIX on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Amit Kumar
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Amit Kumar
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000715446
- Issuer location
- San Jose, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Anixa Biosciences Inc (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Amit Kumar
Disclosed value leader
Amit Kumar
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 16%
13D/G row: Amit Kumar
Showing 1-8 of 50 holder rows.
Quick read
Amit Kumar leads the comparable SEC ownership view at 16%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Amit Kumar's linked filing trail.
Comparable ownership
Top 5
Amit Kumar
16%
Michael J. Catelani
7%
VANGUARD CAPITAL MANAGEMENT LLC
3.8%
UBS Group AG
1.7%
Laird Norton Wetherby Trust Compa...
1.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Amit Kumar |
13D/G
3/4/5
Chief Executive Officer, Director
|
16%
|
$16,667,362
6,173,097 shares
|
+$1,403,336 | 04 Jun 2025 |
| Michael J. Catelani |
13D/G
3/4/5
Michael Catelani · President, COO & CFO
|
7%
|
$10,662,205
2,468,103 shares
|
$0 | 05 Jan 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
3.8%
|
$3,723,586
1,329,852 shares
|
— | 30 Jun 2026 |
| UBS Group AG |
13F
Company
|
1.7%
|
$1,639,204
585,430 shares
|
— | 30 Jun 2026 |
| Laird Norton Wetherby Trust Company, LLC |
13F
Company
|
1.6%
|
$1,620,436
578,727 shares
|
— | 30 Jun 2026 |
| D.A. DAVIDSON & CO. |
13F
Company
|
1.5%
|
$1,509,962
539,272 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1%
|
$1,006,247
359,194 shares
|
— | 30 Jun 2026 |
| MARSHALL WACE, LLP |
13F
Company
|
0.93%
|
$919,332
328,332 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$230,185.
Buys
$230,185
Insiders: 3
Sells
$0
Insiders: 0
Net
+$230,185
Shares: +74,821
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 74,821
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 64,821 | 0 | $199,785 | $0 | +$199,785 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 10,000 | 0 | $30,400 | $0 | +$30,400 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-5 of 5 reporting-owner rows connected to Anixa Biosciences Inc. Open a relationship link for the CIK-to-CIK filing trail.
Rows
5
Largest Forms 3/4/5 holder
Lewis H. Titterton Jr.
Net 12M change
+$230,185
Latest report
31 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Lewis H. Titterton Jr. | Director | $3,424,775 | +$58,301 | +1.7% | Filing P/S | 20 Jul 2026 |
| Amit Kumar | Chief Executive Officer, Director | $2,279,790 | +$141,484 | +6.6% | Filing P/S | 31 Jul 2026 |
| Arnold M. Baskies | Director | $379,601 | +$30,400 | +8.7% | Median | 27 Jul 2026 |
| Michael J. Catelani | President, COO & CFO | $95,675 | Filing P/S | 05 Jan 2026 | ||
| Emily Gottschalk | Director | Mixed | 05 Jan 2026 |
Recent insider transactions for Anixa Biosciences Inc
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Amit Kumar | ANIX | Common Stock | Purchase | 0.77% | $17,350 | $3.47 | 5,000 | 657,000 | 31 Jul 2026 | Direct |
| Arnold M. Baskies | ANIX | Common Stock | Tax liability | -3.85% | -5,428 | 135,572 | 27 Jul 2026 | Direct | ||
| Arnold M. Baskies | ANIX | Common Stock | Options Exercise | 4.44% | 6,000 | 141,000 | 27 Jul 2026 | Direct | ||
| Arnold M. Baskies | ANIX | Employee Stock Option (Right to Buy) | Options Exercise | -100% | -6,000 | 0 | 27 Jul 2026 | Direct | ||
| Amit Kumar | ANIX | Common Stock | Purchase | 0.77% | $17,200 | $3.44 | 5,000 | 652,000 | 27 Jul 2026 | Direct |
| Amit Kumar | ANIX | Common Stock | Purchase | 0.5% | $10,744 | $3.37 | 3,188 | 647,000 | 27 Jul 2026 | Direct |
| Amit Kumar | ANIX | Common Stock | Purchase | 0.47% | $11,190 | $3.73 | 3,000 | 643,812 | 24 Jul 2026 | Direct |
| Amit Kumar | ANIX | Common Stock | Purchase | 0.79% | $17,300 | $3.46 | 5,000 | 640,812 | 20 Jul 2026 | Direct |
| Lewis H. Titterton Jr. | ANIX | Common Stock | Purchase | 1.23% | $41,640 | $3.47 | 12,000 | 986,967 | 20 Jul 2026 | Direct |
| Lewis H. Titterton Jr. | ANIX | Common Stock | Purchase | 0.29% | $9,174 | $3.28 | 2,797 | 974,967 | 15 Jul 2026 | Direct |
| Amit Kumar | ANIX | Common Stock | Purchase | 0.79% | $15,200 | $3.04 | 5,000 | 635,812 | 10 Jul 2026 | Direct |
| Lewis H. Titterton Jr. | ANIX | Common Stock | Purchase | 0.29% | $7,487 | $2.64 | 2,836 | 972,170 | 16 Jun 2026 | Direct |
| Amit Kumar | ANIX | Common Stock | Purchase | 3.44% | $52,500 | $2.50 | 21,000 | 630,812 | 12 Jun 2026 | Direct |
| Arnold M. Baskies | ANIX | Common Stock | Purchase | 8% | $30,400 | $3.04 | 10,000 | 135,000 | 28 Jan 2026 | Direct |
| Lewis H. Titterton Jr. | ANIX | Employee Stock Option | Award | 25,000 | 25,000 | 05 Jan 2026 | Direct | |||
| Amit Kumar | ANIX | Employee Stock Option | Award | 350,000 | 350,000 | 05 Jan 2026 | Direct | |||
| Emily Gottschalk | ANIX | Employee Stock Option | Award | 25,000 | 25,000 | 05 Jan 2026 | Direct | |||
| Michael J. Catelani | ANIX | Employee Stock Option | Award | 175,000 | 175,000 | 05 Jan 2026 | Direct | |||
| Arnold M. Baskies | ANIX | Employee Stock Option | Award | 25,000 | 25,000 | 05 Jan 2026 | Direct | |||
| Lewis H. Titterton Jr. | ANIX | Common Stock | Options Exercise | 1.68% | 16,000 | 969,334 | 15 Dec 2025 | Direct | ||
| Lewis H. Titterton Jr. | ANIX | Employee Stock Option | Options Exercise | -100% | -16,000 | 0 | 15 Dec 2025 | Direct | ||
| Amit Kumar | ANIX | Common Stock | Tax liability | -21.7% | -169,439 | 610,486 | 30 Oct 2025 | Direct | ||
| Amit Kumar | ANIX | Common Stock | Options Exercise | 34.5% | 200,000 | 779,925 | 30 Oct 2025 | Direct | ||
| Amit Kumar | ANIX | Employee Stock Option (Right to Buy) | Options Exercise | -100% | -200,000 | 0 | 30 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.